What is L&G Pharma Breakthrough UCITS ETF
L&G Pharma Breakthrough UCITS ETF falls under the Sector Equity Biotechnology category, with the top three holdings being Travere Therapeutics Inc (5.5%), Xencor Inc (5.2%) and Halozyme Therapeutics Inc (3.6%). Over the past 12 months, the fund has returned +32.5%.
Frequently asked questions
Does this ETF pay dividends or reinvest them?
This ETF is distributing: it periodically pays out dividends received to investors. You can also see this in the fund's name or in the "Distribution policy" field further up this page.
What's the annual cost (TER) of this ETF?
This ETF's TER (Total Expense Ratio) is 0.49% annual — the annual fee deducted automatically by the fund, already reflected in the price.
How is this ETF taxed in the UK?
Held outside an ISA or SIPP, gains are generally subject to Capital Gains Tax and income may be subject to dividend tax depending on the fund's distribution policy — see our dedicated UK tax guide. Held within an ISA, both are entirely exempt.
